XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)		1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 07, 2019 USD ($) multiplier item	Sep. 30, 2019 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Agreements
Payments of consideration under RPAs, AAAs and CPPAs					$ 37,000,000	$ 14,650,000
Contingent consideration under RPAs, AAAs and CPPAs			$ 4,000,000		4,000,000		$ 7,000,000
Short-term royalty and commercial payment receivables			12,682,000		12,682,000		14,215,000
Royalty purchase agreement asset impairment			$ 14,000,000		$ 23,000,000	$ 1,575,000
Aronora \| Royalty Purchase Agreement
Agreements
Number of drug candidates \| item	5
Non-royalties to be received (as a percent)	10.00%
Future non-royalty payments to be received (as a percent)	5.00%
Multiplier for cumulative amount of consideration paid \| multiplier	2
Payments of consideration under RPAs, AAAs and CPPAs	$ 6,000,000.0	$ 3,000,000.0
Threshold amount of cumulative royalties on net sales per product	250,000,000.0
Maximum royalty milestone payments to be paid per product	85,000,000.0
Acquisition of royalty and commercial payment receivables, Long-Term	9,000,000.0
Contingent consideration under RPAs, AAAs and CPPAs	3,000,000.0
Royalty purchase agreement asset impairment				$ 9,000,000.0
Amount of increase in allowance for credit loss				9,000,000.0
Allowance for credit losses							$ 0
Decrease in long-term royalty and commercial rights receivables due to impairment				$ 9,000,000.0
Aronora \| Royalty Purchase Agreement \| Minimum
Agreements
Threshold amount of cumulative royalties on net sales per product	25,000,000.0
Aronora \| Royalty Purchase Agreement \| SVB Loan
Agreements
Payments of consideration under RPAs, AAAs and CPPAs	$ 3,000,000.0
Aronora \| Royalty Purchase Agreement \| Bayer Products
Agreements
Number of drug candidates \| item	3
Number of drug candidates subject to exclusive license option \| item	1
Royalties entity has right to receive (as a percent)	100.00%
Non-royalties to be received (as a percent)	10.00%
Contingent future cash payment for each product	$ 1,000,000.0
Aronora \| Royalty Purchase Agreement \| Bayer Products \| Maximum
Agreements
Contingent consideration under RPAs, AAAs and CPPAs	$ 3,000,000.0
Aronora \| Royalty Purchase Agreement \| Non-Bayer Products
Agreements
Number of drug candidates	2
Non-royalties to be received (as a percent)	10.00%